Charles Russell Speechlys advises Kreos Capital on its €15 million growth capital investment
Charles Russell Speechlys LLP advised Kreos Capital V (UK) Limited on its €15 million growth capital investment in Kiadis Pharma NV (“Kiadis Pharma”), a Dutch company listed on Euronext Amsterdam and Euronext Brussels.
Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders. Its product candidates have the potential to make allogeneic hematopoietic stem cell transplantations (HSCT) safer and more effective for patients.
Kiadis Pharma announced to the market that it will use the financing to advance the development of its ATIR products, for general corporate purposes and to repay €5.3 million of existing Dutch Government Loans.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Senior Associate) and Amelly Kok (Associate) from our Corporate Team. Fruytier Lawyers in Business advised on matters of Dutch law and Borden Ladner Gervais LLP on matters of Canadian law respectively.
News & Insights
Charles Russell Speechlys advises Civica on acquisition of Trac Systems
The Corporate team has advised longstanding client, Civica Group, on its latest acquisition Trac Systems and its subsidiary Zedcore Systems.
Charles Russell Speechlys advises Civica Group on acquisition of Electoral Reform Services
Charles Russell Speechlys has advised longstanding client, the Civica Group on its latest acquisition of Electoral Reform Services Limited.
Things to consider when your pharmacy lease ends
Aidan Welton and Richard Flenley look at various lease provisions that need to be fulfilled.